Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status

Na Liu, Zhaowei Meng, Qiang Jia, Jian Tan, Guizhi Zhang, Wei Zheng, Renfei Wang, Xue Li, Tianpeng Hu, Arun Upadhyaya, Pingping Zhou, Sen Wang, Na Liu, Zhaowei Meng, Qiang Jia, Jian Tan, Guizhi Zhang, Wei Zheng, Renfei Wang, Xue Li, Tianpeng Hu, Arun Upadhyaya, Pingping Zhou, Sen Wang

Abstract

131I treatment is an important management method for patients with differentiated thyroid cancer (DTC). Unsuccessful 131I ablation drastically affects the prognosis of the patients. This study aimed to analyze potential predictive factors influencing the achievement of a disease-free status following the first 131I therapy. This retrospective review included 315 DTC patients, and multiple factors were analyzed. Tumor size, pathological tumor stage, lymph node (LN) metastasis, distant metastasis, American Thyroid Association recommended risks, pre-ablation thyroglobulin (Tg), and thyroid stimulating hormone (TSH) displayed significant differences between unsuccessful and successful group. Cutoff values of Tg and TSH to predict a successful outcome were 3.525 ng/mL and 99.700 uIU/ml by receiver operating characteristic curves analysis. Binary logistic regression analysis showed that tumor stage T3 or T4, LN metastasis to N1b station, intermediate and high risks, pre-ablation Tg ≥ 3.525 ng/ml and TSH <99.700 μIU/mL were significantly associated with unsuccessful outcomes. Logistic regression equation for achieving a disease-free status could be rendered as: y (successful treatment) = -0.270-0.503 X1 (LN metastasis) -0.236 X2 (Tg) + 0.015 X3 (TSH). This study demonstrated LN metastasis, pre-ablation Tg and TSH were the most powerful predictors for achieving a disease-free status by the first 131I therapy.

Figures

Figure 1
Figure 1
Diagnostic values of pre-ablation thyroglobulin (A) and thyroid stimulating hormone (B) analyzed by receiver operating characteristic curves.

References

    1. Siegel R. L., Miller K. D. & Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians 66, 7–30, doi: 10.3322/caac.21332 (2016).
    1. Gharib H. et al.. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Journal of endocrinological investigation 33, 51–56 (2010).
    1. American Thyroid Association Guidelines Taskforce on Thyroid N. et al.. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: official journal of the American Thyroid Association 19, 1167–1214, doi: 10.1089/thy.2009.0110 (2009).
    1. Pacini F. et al.. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European journal of endocrinology/European Federation of Endocrine Societies 154, 787–803, doi: 10.1530/eje.1.02158 (2006).
    1. Haugen B. R. et al.. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid: official journal of the American Thyroid Association 26, 1–133, doi: 10.1089/thy.2015.0020 (2016).
    1. Meng Z. & Song X. Reply to: Meta-analysis on Successful Ablation After Low- Versus High-Dose Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma. Clinical nuclear medicine 41, 675, doi: 10.1097/RLU.0000000000001190 (2016).
    1. Song X. et al.. Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer: A Meta-analysis. Clinical nuclear medicine 40, 774–779, doi: 10.1097/RLU.0000000000000914 (2015).
    1. Fard-Esfahani A. et al.. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nuclear medicine communications 35, 808–817, doi: 10.1097/MNM.0000000000000132 (2014).
    1. Hakala T. T. et al.. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. International journal of clinical oncology 21, 231–239, doi: 10.1007/s10147-015-0904-6 (2016).
    1. Rosario P. W., Xavier A. C. & Calsolari M. R. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and (1)(3)(1)I activity in patients with thyroid cancer and low risk of recurrence. Thyroid: official journal of the American Thyroid Association 21, 49–53, doi: 10.1089/thy.2010.0145 (2011).
    1. Rosario P. W., Mineiro Filho A. F., Prates B. S., Silva L. C. & Calsolari M. R. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid: official journal of the American Thyroid Association 22, 1140–1143, doi: 10.1089/thy.2012.0190 (2012).
    1. Schlumberger M. et al.. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. The New England journal of medicine 366, 1663–1673, doi: 10.1056/NEJMoa1108586 (2012).
    1. Mallick U. et al.. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. The New England journal of medicine 366, 1674–1685, doi: 10.1056/NEJMoa1109589 (2012).
    1. Kendler D. B., Vaisman F., Corbo R., Martins R. & Vaisman M. Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer. Clinical nuclear medicine 37, 545–549, doi: 10.1097/RLU.0b013e31824852f8 (2012).
    1. Gonzalez C. et al.. Thyroglobulin as early prognostic marker to predict remission at 18–24 months in differentiated thyroid carcinoma. Clinical endocrinology 80, 301–306, doi: 10.1111/cen.12282 (2014).
    1. Lee J. I. et al.. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. Surgery 153, 828–835, doi: 10.1016/j.surg.2012.12.008 (2013).
    1. Webb R. C. et al.. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. The Journal of clinical endocrinology and metabolism 97, 2754–2763, doi: 10.1210/jc.2012-1533 (2012).
    1. Vrachimis A., Riemann B., Mader U., Reiners C. & Verburg F. A. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. European journal of nuclear medicine and molecular imaging, doi: 10.1007/s00259-015-3223-2 (2015).
    1. Hasbek Z. & Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success? Molecular imaging and radionuclide therapy 25, 79–84, doi: 10.4274/mirt.88598 (2016).
    1. Winter J. et al.. Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation activity. Clinical endocrinology, doi: 10.1111/cen.13123 (2016).
    1. Besic N., Pilko G., Petric R., Hocevar M. & Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. Journal of surgical oncology 97, 221–225, doi: 10.1002/jso.20935 (2008).
    1. Zheng W., Tan J. & Zhang G. Extensive bone metastases as the initial symptom of papillary thyroid microcarcinoma: A case report. Experimental and therapeutic medicine 9, 2104–2108, doi: 10.3892/etm.2015.2423 (2015).
    1. Chung Y. S. et al.. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid: official journal of the American Thyroid Association 19, 241–246, doi: 10.1089/thy.2008.0244 (2009).
    1. Podnos Y. D., Smith D., Wagman L. D. & Ellenhorn J. D. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. The American surgeon 71, 731–734 (2005).
    1. Zaydfudim V., Feurer I. D., Griffin M. R. & Phay J. E. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 144, 1070–1077; discussion 1077–1078, doi: 10.1016/j.surg.2008.08.034 (2008).
    1. Lundgren C. I., Hall P., Dickman P. W. & Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106, 524–531, doi: 10.1002/cncr.21653 (2006).
    1. Leboulleux S. et al.. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. The Journal of clinical endocrinology and metabolism 90, 5723–5729, doi: 10.1210/jc.2005-0285 (2005).
    1. Qiu Z. L., Shen C. T. & Luo Q. Y. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy. Thyroid: official journal of the American Thyroid Association 25, 229–237, doi: 10.1089/thy.2014.0233 (2015).
    1. Lim I. et al.. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer. Annals of nuclear medicine 26, 777–786, doi: 10.1007/s12149-012-0640-1 (2012).
    1. Edmonds C. J., Hayes S., Kermode J. C. & Thompson B. D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. The British journal of radiology 50, 799–807, doi: 10.1259/0007-1285-50-599-799 (1977).
    1. Verburg F. A. et al.. The thyroid axis ‘setpoints’ are significantly altered after long-term suppressive LT4 therapy. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 46, 794–799, doi: 10.1055/s-0034-1375678 (2014).
    1. Spencer C., Petrovic I. & Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. The Journal of clinical endocrinology and metabolism 96, 1283–1291, doi: 10.1210/jc.2010-2762 (2011).

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera